News

31. Daiichi Sankyo And Lilly Announce TRILOGY ACS Results Regarding Effient (Prasugrel) In Acute Coronary Syndrome UA/NSTEMI Patients To Be Managed Medically Without An Artery-Opening Procedure 8/26/2012

    Daiichi Sankyo Company, Limited, and Eli Lilly and Company recently announced data from the TRILOGY ACS study, a phase III trial comparing prasugrel plus aspirin to clopidogrel plus aspirin in patients with unstable angina (UA) or non-ST elevation myocardial infarction (NSTEMI), who were managed medically without an arteryopening procedure.

32. As Tuberculosis Grows More Difficult To Control, Vaccine Candidate To Prevent Disease Enters Clinical Testing 8/22/2012

     Aeras and the Infectious Disease Research Institute (IDRI) announce today the start of the first clinical trial of IDRI's novel tuberculosis vaccine candidate, ID93 + GLA-SE. The Phase I clinical trial will assess the safety, tolerability and immunogenicity of the vaccine candidate in 60 healthy adult volunteers. The study will be conducted by Johnson County Clin-Trials in Lenexa, Kansas, in close collaboration with Aeras and IDRI.

33. Pluristem's PLX Cells Show Efficacy In Treating Lung Disease 7/31/2012

    Pluristem Therapeutics, Inc. (NASDAQ:PSTI; TASE: PLTR), a leading developer of placenta-based cell therapies, recently announced the results of new preclinical tests that show its PLacental eXpanded (PLX) cells may be effective in reducing pulmonary fibrosis and improving lung function in a group of diseases collectively called interstitial lung disease (ILD). ILD includes the pulmonary insults occurring in the lung following its exposure to drugs, radiation or toxic chemicals and the pulmonary complications of systemic autoimmune diseases. 

34. Inovio Initiates H1N1 Universal Influenza Vaccine Clinical Trial Targeting Over-65 Population, Which Represents 90% Of Flu Deaths 7/10/2012
35. Titan Completes Preclinical Study Of A Continuous, Dopamine Agonist Treatment for Parkinson's Disease 7/10/2012

    Titan Pharmaceuticals, Inc. (OTCBB: TTNP) today announced that it has successfully completed investigation into the feasibility of a long-term, round-the-clock, non-fluctuating dopamine agonist treatment for Parkinson's disease. The preclinical study was primarily funded by a $495,000 grant awarded to Titan by the National Institutes of Health (NIH) under the Small Business Innovation Research (SBIR) program, and administered by the National Institute of Neurological Disorders and Stroke (NINDS).

36. Boston Therapeutics Completes Enrollment In Phase ll Clinical Trial To Evaluate PAZ320 In Patients With Type 2 Diabetes 6/22/2012

    Boston Therapeutics, Inc. (OTCQB: BTHE) (OTCBB: BTHE) ("Boston Therapeutics" or "The Company"), a developer of complex carbohydrates to treat diabetes and inflammatory diseases, today announced it has completed enrollment in a Phase ll clinical trial to evaluate the safety and efficacy of PAZ320 when added to oral agents or insulin in patients with Type 2 diabetes at Dartmouth-Hitchcock Medical Center in Lebanon, NH. PAZ320 is a non-systemic chewable tablet designed to reduce post-meal elevation of blood glucose.

37. Halozyme Presents Positive Data From Two Ultrafast Insulin Clinical Trials With Human Hyaluronidase Enzyme - rHuPH20 - At ADA 2012 6/9/2012

    Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced the presentation of two posters at the 72nd Scientific Sessions of the American Diabetes Association (ADA) highlighting its research on improved treatment options for both the multiple daily injection therapy and continuous subcutaneous insulin infusion markets.

38. Abbott Announces Initiation Of Phase 3 Study Of Elagolix In Patients With Endometriosis 6/5/2012

    Abbott (NYSE: ABT), in cooperation with Neurocrine Biosciences, Inc. (NASDAQ: NBIX), today announced the initiation of a pivotal Phase 3 clinical trial designed to evaluate the safety and efficacy of elagolix in female patients with endometriosis. Elagolix is an oral gonadotropin-releasing hormone (GnRH) antagonist.

39. New Mobile App Helps Doctors Find Clinical Trials For Cancer Patients 6/1/2012

    oday, Eli Lilly and Company (NYSE: LLY) launched a searchable clinical trial mobile application for oncology healthcare professionals. 

40. Elevation Pharmaceuticals Announces Positive Phase 2b Results For EP-101 For The Treatment Of Chronic Obstructive Pulmonary Disease (COPD) 5/16/2012

    Elevation Pharmaceuticals, Inc., a pharmaceutical company focused on the development of new aerosol therapies for patients with respiratory diseases, announced today positive results from a Phase 2b study of EP-101 in patients with chronic obstructive pulmonary disease (COPD), a progressive disease comprising chronic bronchitis and emphysema caused largely by smoking.